GlassScriptPhysician profile
Barbara M Leighton
NPI 1487751475
$13,115.95
in general payments reported to CMS, 2019-2025
41 companies · $3,020 in 2025
The $3,020 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $1,374 · 2021: $1,279 · 2022: $1,833 · 2023: $2,015 · 2024: $2,063 · 2025: $3,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,944 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,943.70 |
| Education | $154.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,062.52 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,245.29 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,136.86 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $695.44 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $680.50 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $649.08 | 2019-2025 | Dupixent |
| Genzyme Corporation | $558.05 | 2020-2025 | |
| Insmed, INC. | $432.63 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $378.33 | 2021-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $293.08 | 2020-2025 | Aralast, Glassia |
| United Therapeutics Corporation | $270.57 | 2019-2024 | Tyvaso |
| Mylan Specialty L.P. | $255.05 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $216.33 | 2020-2025 | Acthar |
| Verona Pharma, INC. | $213.70 | 2025 | Ohtuvayre |
| Amgen INC. | $212.97 | 2021-2025 | Tezspire |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $160.39 | 2019-2021 | |
| Grifols USA, LLC | $158.94 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Philips North America LLC | $158.47 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Electromed, INC. | $146.33 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $102.26 | 2020-2024 | Xolair |
| Ani Pharmaceuticals, INC. | $100.02 | 2023-2025 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $98.51 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $97.81 | 2019-2025 | Winrevair |
| Advanced Respiratory, INC | $86.41 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Sunovion Pharmaceuticals INC. | $67.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.98 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.85 | 2022 | |
| Viatris Specialty LLC | $60.14 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $59.14 | 2019-2024 | Injectafer |
| Axsome Therapeutics, INC. | $54.93 | 2023-2024 | Sunosi |
| Pulmonx Corporation | $42.32 | 2023-2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Shire North American Group INC | $38.31 | 2019 | |
| Vifor Pharma, INC. | $37.17 | 2025 | Zemaira |
| Inogen, INC. | $28.76 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $25.40 | 2020 | |
| Teleflex LLC | $22.77 | 2024 | Urolift |
| Phadia US INC. | $20.81 | 2024 | Immunocap |
| Mallinckrodt Enterprises LLC | $17.05 | 2019 | |
| Pfizer INC. | $16.54 | 2019 | |
| Immunitybio, INC. | $15.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Leighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.